



Poly Medicure Ltd.

POLYMED
Medical Devices

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate, Phase - III, New Delhi - 110020, INDIA
Tel : +91-11-26321838, 26321881, 26321899, 26321889, 26321893, Fax : +91-11-26321894, 26321839
E-mail : info@polymedicure.com Website : www.polymedicure.com
CIN : L40300DL1995PLC066923

Dated: 04th February, 2016

Scrip Code : 531768

Scrip Code : POLYMED

The Manager,
Department of Corporate Services,
Bombay Stock Exchange Limited
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.

The Manager,
Department of Corporate Services,
National stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G- Block
Bandra Kurla Complex, Bandra (E), Mumbai-400051

Subject: Outcome of Board Meeting of the Company
Ref: Compliance of Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, We are pleased to inform the Stock Exchange that, the Board of Directors at their meeting held today i.e. 04th February, 2016 at Crowne Plaza Hotels, Community Centre, Okhla, Phase – I, New Delhi – 110020.

- The Board has approved the Unaudited Financial Results along with Limited Review Report for the Third Quarter and Nine Months ended on 31st December, 2015.
- Other Normal Business

Kindly acknowledge the receipt of the same.

Thanking You,

For Poly Medicure Limited

Avinash Chandra
Company Secretary

Encl. As above

Particulars	Quarter ended			Nine Months Ended		Year Ended
	31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
	(Unaudited)			(Unaudited)		(Audited)
1 Income from operations						
a Net sales / income from operations (net of excise duty)	9,058.71	9,949.81	9,577.10	28,459.64	27,097.09	36,730.33
b Other operating income	136.46	96.56	158.50	312.09	481.46	638.50
Total income from operations (net)	9,195.17	10,046.37	9,735.60	28,771.73	27,578.55	37,368.83
2 Expenses						
a Cost of materials consumed	3,045.00	3,479.83	3,642.36	9,967.07	9,812.14	13,127.13
b Purchases of stock-in-trade	210.07	168.06	177.63	521.90	545.11	652.53
c Changes in inventories of finished goods, work-in-progress and stock-in-trade	(156.07)	24.46	(269.55)	(65.47)	(591.74)	(306.83)
d Employee benefits expense	1,758.29	1,715.94	1,589.85	5,045.29	4,551.06	6,030.00
e Depreciation and amortisation expense	497.19	494.81	478.41	1,509.69	1,326.51	1,808.99
f Other expenses	2,376.39	2,589.46	2,381.36	7,471.54	6,930.03	9,602.68
Total expenses	7,730.87	8,472.56	8,000.06	24,450.02	22,573.11	30,914.50
3 Profit from operations before other income, finance costs and exceptional items (1-2)	1,464.30	1,573.81	1,735.54	4,321.71	5,005.44	6,454.33
4 Other income	173.99	299.08	397.35	644.24	698.73	822.14
5 Profit from ordinary activities before finance costs and exceptional items (3 + 4)	1,638.29	1,872.89	2,132.89	4,965.95	5,704.17	7,276.47
6 Finance costs	220.04	153.26	279.95	572.79	648.52	822.65
7 Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	1,418.25	1,719.63	1,852.94	4,393.16	5,055.65	6,453.82
8 Exceptional items	-	-	-	-	1,957.80	1,957.80
9 Profit from ordinary activities before tax (7 + 8)	1,418.25	1,719.63	1,852.94	4,393.16	7,013.45	8,411.62
10 Tax expense	364.66	458.42	659.70	1,102.98	2,122.10	2,309.90
11 Net Profit from ordinary activities after tax (9 - 10)	1,053.59	1,261.21	1,193.24	3,290.18	4,891.35	6,101.72
12 Extraordinary items	-	-	-	-	-	-
13 Net Profit for the period (11 + 12)	1,053.59	1,261.21	1,193.24	3,290.18	4,891.35	6,101.72
14 Paid-up equity share capital (Face Value of ₹ 5 each)	2,205.67	2,205.67	2,205.67	2,205.67	2,205.67	2,205.67
15 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year.	-	-	-	-	-	16,991.29
16 Earnings per share (before extraordinary items) (Yearly annualised, Qtr and Nine months not annualised) :						
Basic (₹)	2.39	2.86	2.69	7.46	11.09	13.83
Diluted (₹)	2.39	2.86	2.69	7.46	11.09	13.83

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 4th Feb 2016.
- The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.
- The statutory Auditors have carried out the limited review of the above results.
- Tax Expenses includes Current Tax, Deferred Tax and Reversal of tax relating to earlier years.
- The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.

Himanshu Baid



Himanshu Baid
Managing Director
DIN : 00014008

Place : New Delhi
Date : 04.02.2016



DOOGAR & ASSOCIATES

Chartered Accountants

LIMITED REVIEW REPORT

The Board of Directors

Poly Medicure Limited
232B, 3rd Floor, Okhla Industrial Estate,
Phase III, New Delhi – 110 020.

Dear Sirs,

1. We have reviewed the accompanying statement of unaudited financial results of Poly Medicure Limited (the 'Company') for the quarter ended December 31, 2015. This statement has been prepared by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initiated by us for identification purposes. These unaudited financial statements are the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to issue a report on these unaudited financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results of the company prepared in accordance with applicable accounting standards notified under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the "Listing Regulations, 2015", including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place of signature: New Delhi
Date of signature: 04/02/2016.

For Doogar & Associates
Chartered Accountants
Reg. No. 000561N


(M. S. Agarwal)
Partner
M. No. 86580

